Quick Answer
Serina Therapeutics, Inc. reported Operating Income Loss of -$24.02 million for the year ending 2025.
- Serina Therapeutics, Inc. showed a decrease of -40.9% in Operating Income Loss from 2024 to 2025.
- This data is from Serina Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 25, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$3.55 million | Q2 2018: -$2.13 million | Q3 2018: -$2.20 million | Q1 2019: -$3.12 million | Q2 2019: -$3.44 million | Q3 2019: -$3.28 million | Q1 2020: -$3.01 million | Q2 2020: -$2.37 million | Q3 2020: -$2.40 million | Q1 2021: -$2.19 million | Q2 2021: -$2.21 million | Q3 2021: -$1.67 million | Q1 2022: -$2.05 million | Q2 2022: -$1.59 million | Q3 2022: -$1.55 million | Q1 2023: -$962.0 thousand | Q2 2023: -$945.0 thousand | Q3 2023: -$1.46 million | Q1 2024: -$2.32 million | Q2 2024: -$3.87 million | Q3 2024: -$5.31 million | Q1 2025: -$5.86 million | Q2 2025: -$5.57 million | Q3 2025: -$6.39 million.
- Over the full 9 years of available data (2017 to 2025), Serina Therapeutics, Inc.'s Operating Income Loss has declined by 260.5%.
- Historical annual values: Fiscal year 2025: -$24.02 million | Fiscal year 2024: -$17.05 million | Fiscal year 2023: -$3.13 million | Fiscal year 2022: -$6.98 million | Fiscal year 2021: -$7.93 million | Fiscal year 2020: -$10.10 million | Fiscal year 2019: -$12.56 million | Fiscal year 2018: -$11.25 million | Fiscal year 2017: -$6.66 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: